Procarbazine is an alkylating drug indicated in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. It is available as capsules for oral use. MedsAcross supplies Procarbazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma. MATULANE is an alkylating drug indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma.
Source: US FDA prescribing information
The precise mode of cytotoxic action of procarbazine has not been clearly defined. After metabolic activation, procarbazine may inhibit the transmethylation of methyl groups of methionine into transfer RNA (t-RNA). The unavailability of t-RNA prevents protein synthesis, and consequently prevents DNA and RNA synthesis. Procarbazine may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which directly damage DNA through an alkylation reaction.
Source: US FDA prescribing information
Recommended Dosage: 100 mg/m 2 orally once a day for adult and pediatric patients. See Full Prescribing Information for dosage modifications for adverse reactions
Source: US FDA prescribing information
MATULANE is contraindicated in patients with known hypersensitivity or anaphylaxis to the drug or drug components. History of known hypersensitivity or anaphylaxis to the drug or drug components
Source: US FDA prescribing information
Myelosuppression: Severe neutropenia, anemia, and thrombocytopenia can occur. Obtain complete blood counts prior to initiation of MATULANE. Secondary Malignancies: Lung cancer, myelodysplastic syndrome, acute myeloid leukemia, and non-Hodgkin lymphoma have been reported. Monitor patients for the development of secondary malignancies during and after treatment with MATULANE. Use in Patients with Renal or Hepatic Impairment: Evaluate renal and hepatic function. Closely monitor for adverse reactions. Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol: Advise patients to avoid consumption of alcohol products containing propylene glycol before, after, and during treatment with MATULANE. Infertility: Male and female reproductive function and fertility may be impaired in patients treated with MATULANE. Advise patients on the potential risks for infertility.
Source: US FDA prescribing information
The following adverse reactions are discussed in more detail elsewhere in the labeling. Myelosuppression. Secondary Malignancies. Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol. Infertility. The following adverse reactions associated with the use of MATULANE were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions for MATULANE are neutropenia, anemia, thrombocytopenia, nausea, and vomiting.
Source: US FDA prescribing information
Central nervous system depressants: monitor signs and symptoms of neurotoxicity. Monoamine oxidase (MAO) inhibitors: avoid MAO inhibitors and other drugs with MAO inhibition activity within two weeks before and during treatment with MATULANE. Alcohol: avoid consumption of alcohol or products containing propylene glycol before, after, and during therapy with MATULANE. Tyramine-containing foods: avoid concomitant use.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15°C–30°C (59°F–86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Procarbazine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Matulane 50 mg capsuleOral | Leadiant Biosciences | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 22 July 1969 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Procarbazine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Procarbazine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Procarbazine, including Matulane.
Yes. The US FDA first approved Procarbazine on 22 July 1969, according to Drugs@FDA.
No listed presentation of Procarbazine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Procarbazine is classified under ATC code L01XB01 (Procarbazine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.